Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TScan Therapeutics, Inc. (TCRX)
USD0.91
-0.02 (-1.81%)
US NASDAQ Healthcare Biotechnology
Address
830 Winter Street 2451
Waltham, MA, US
Waltham, MA, US
CEO
Gavin MacBeath
Website
tscan.com
IPO
2021-07-16
CIK 1783328 ISIN US89854M1018
Description
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.91
-0.02 (-1.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
873.2K
Beta
1.03
Float Shares
47.79M
Free Float %
85.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.35% | -6.35% | +12.38% | +26.30% | -0.84% | +18.00% | -13.87% | -69.97% | -88.76% | -88.76% | -88.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
0.91
Low
3.00
+228.5%
Consensus
7.50
+721.3%
Median
7.50
+721.3%
High
12.00
+1,214.1%
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
7.50
+721.3%
|
Quality scores
Altman Z-Score
-4.59
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+266.7% ★ Q1'26: -54.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+12.3% Q1'26: +15.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,518.3% Q1'26: -2,479.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,315.4% Q1'26: -2,967.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-209.4% Q1'26: -405.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+16.0% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.71× Q1'26: -0.53× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.14M
est: 11.32M (-10.4%)
|
13.54M
est: 13.89M (-2.6%)
|
21.05M
est: 12.20M (+72.5%)
|
2.82M
est: 3.61M (-22.0%)
|
10.33M
est: 11.15M (-7.4%)
|
7.56M
1.09M – 12.10M
-32.2% YoY
|
7.81M
6.74M – 8.87M
+3.3% YoY
|
26.27M
19.23M – 32.54M
+236.5% YoY
|
49.07M
35.91M – 60.78M
+86.8% YoY
|
86.48M
63.29M – 107.12M
+76.2% YoY
|
| EBITDA |
-45.30M
est: -11.32M (-300.2%)
|
-59.91M
est: -13.89M (-331.2%)
|
-80.10M
est: -12.20M (-556.5%)
|
-119.74M
est: -3.61M (-3,218.2%)
|
-132.95M
est: -11.15M (-1,092.2%)
|
-7.56M
-12.10M – -1.09M
+32.2% YoY
|
-7.81M
-8.87M – -6.74M
-3.3% YoY
|
-26.27M
-32.54M – -19.23M
-236.5% YoY
|
-49.07M
-60.78M – -35.91M
-86.8% YoY
|
-86.48M
-107.12M – -63.29M
-76.2% YoY
|
| EBIT |
-48.63M
est: -11.32M (-329.6%)
|
-65.05M
est: -13.89M (-368.2%)
|
-85.46M
est: -12.20M (-600.5%)
|
-123.85M
est: -3.61M (-3,332.1%)
|
-135.81M
est: -11.15M (-1,117.9%)
|
-7.56M
-12.10M – -1.09M
+32.2% YoY
|
-7.81M
-8.87M – -6.74M
-3.3% YoY
|
-26.27M
-32.54M – -19.23M
-236.5% YoY
|
-49.07M
-60.78M – -35.91M
-86.8% YoY
|
-86.48M
-107.12M – -63.29M
-76.2% YoY
|
| Net Income |
-48.63M
est: -715.84M (+93.2%)
|
-66.22M
est: -322.61M (+79.5%)
|
-89.22M
est: -251.24M (+64.5%)
|
-127.50M
est: -164.51M (+22.5%)
|
-129.77M
est: -157.73M (+17.7%)
|
-115.07M
-210.73M – -104.76M
+27.0% YoY
|
-124.82M
-153.73M – -107.00M
-8.5% YoY
|
-127.31M
-136.33M – -93.89M
-2.0% YoY
|
-85.71M
-112.30M – -55.83M
+32.7% YoY
|
-52.38M
-68.62M – -34.12M
+38.9% YoY
|
| SGA |
13.83M
est: 47.06M (-70.6%)
|
20.35M
est: 57.76M (-64.8%)
|
25.49M
est: 43.12M (-40.9%)
|
29.56M
est: 12.75M (+131.7%)
|
31.99M
est: 39.42M (-18.8%)
|
26.71M
3.87M – 42.77M
-32.2% YoY
|
27.60M
23.82M – 31.34M
+3.3% YoY
|
92.86M
67.96M – 115.01M
+236.5% YoY
|
173.45M
126.94M – 214.84M
+86.8% YoY
|
305.68M
223.71M – 378.61M
+76.2% YoY
|
| EPS |
-2.03
est: -6.39 (+68.2%)
|
-2.74
est: -2.76 (+0.7%)
|
-1.36
est: -1.97 (+31.1%)
|
-1.14
est: -1.27 (+10.4%)
|
-1.00
est: -1.21 (+17.7%)
|
-1.02
-1.62 – -0.81
+16.0% YoY
|
-0.97
-1.18 – -0.82
+5.3% YoY
|
-0.86
-1.05 – -0.72
+11.5% YoY
|
-0.66
-0.86 – -0.43
+22.8% YoY
|
-0.40
-0.53 – -0.26
+38.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-109.24M
OE per share TTM
-0.84
Owner's Yield
-67.27%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
421.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
59
Total invested
30.69M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 5.22M | 12.20% | — | 5.22M | — | — | PN | Delaware | 2023-06-02 | ↗ |
| 2 | Weston Nichols | 5.22M | 12.20% | — | 5.22M | — | — | IN | Delaware | 2023-06-02 | ↗ |
| 3 | EcoR1 Capital, LLC | 5.00M | 11.00% | — | 5.00M | — | 5.00M | IA, OO | Delaware | 2023-06-05 | ↗ |
| 4 | Oleg Nodelman | 5.00M | 11.00% | — | 5.00M | — | 5.00M | HC, IN | Delaware | 2023-06-05 | ↗ |
| 5 | EcoR1 Capital Fund Qualified, L.P. | 4.64M | 11.00% | — | 4.64M | — | 4.64M | PN | Delaware | 2023-06-05 | ↗ |
| 6 | (1) BlackRock, Inc. | 4.63M | 9.50% | 4.36M | — | — | — | HC | Delaware | 2024-11-08 | ↗ |
| 7 | BVF Inc. | 4.41M | 9.99% | — | — | — | 4.41M | CO | Delaware | 2023-06-05 | ↗ |
| 8 | BVF Partners L.P. | 4.41M | 9.99% | — | — | — | 4.41M | IA, PN | Delaware | 2023-06-05 | ↗ |
| 9 | Mark N. Lampert | 4.41M | 9.99% | — | — | — | 4.41M | IN | Delaware | 2023-06-05 | ↗ |
| 10 | BVF GP Holdings LLC | 4.23M | 9.60% | — | — | — | 4.23M | OO | Delaware | 2023-06-05 | ↗ |
| 11 | Adage Capital Advisors, L.L.C. | 4.00M | 9.35% | — | 4.00M | — | — | OO | Delaware | 2023-06-12 | ↗ |
| 12 | Adage Capital Partners GP, L.L.C. | 4.00M | 9.35% | — | 4.00M | — | — | OO | Delaware | 2023-06-12 | ↗ |
| 13 | Adage Capital Partners, L.P. | 4.00M | 9.35% | — | 4.00M | — | — | PN | Delaware | 2023-06-12 | ↗ |
| 14 | Phillip Gross | 4.00M | 9.35% | — | 4.00M | — | — | IN | Delaware | 2023-06-12 | ↗ |
| 15 | Robert Atchinson | 4.00M | 9.35% | — | 4.00M | — | — | IN | United States | 2023-06-12 | ↗ |
| 16 | BVF I GP LLC | 3.02M | 6.80% | — | — | — | 3.02M | OO | Delaware | 2023-06-05 | ↗ |
| 17 | Biotechnology Value Fund, L.P. | 3.02M | 6.80% | — | — | — | 3.02M | PN | Delaware | 2023-06-05 | ↗ |
| 18 | Bihua Chen | 2.50M | 5.15% | — | 2.50M | — | 2.50M | IN | United States | 2024-04-29 | ↗ |
| 19 | Cormorant Asset Management, LP | 2.50M | 5.15% | — | 2.50M | — | 2.50M | PN | Cayman Islands | 2024-04-29 | ↗ |
| 20 | Cormorant Global Healthcare GP, LLC | 2.50M | 5.15% | — | 2.50M | — | 2.50M | OO | Delaware | 2024-04-29 | ↗ |
| 21 | Cormorant Global Healthcare Master Fund, LP | 2.50M | 5.15% | — | 2.50M | — | 2.50M | PN | Cayman Islands | 2024-04-29 | ↗ |
| 22 | BVF II GP LLC | 1.21M | 2.80% | — | — | — | 1.21M | OO | Delaware | 2023-06-05 | ↗ |
| 23 | Biotechnology Value Fund II, L.P. | 1.21M | 2.80% | — | — | — | 1.21M | PN | Delaware | 2023-06-05 | ↗ |
| 24 | BVF Partners OS Ltd. | 140.6K | 1.00% | — | — | — | 140.6K | CO | Delaware | 2023-06-05 | ↗ |
| 25 | Biotechnology Value Trading Fund OS LP | 140.6K | 1.00% | — | — | — | 140.6K | PN | Delaware | 2023-06-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
59
-13 vs prev Q
New positions
10
Closed positions
23
Increased
27
Reduced
18
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | LYNX1 CAPITAL MANAGEMENT LP | 8.02M +161.8K (+2.1%) | 8.02M -6.3M (-43.9%) | 6.18% +0.120 pp | 1.62% -1.287 pp | USD2.15 -53.5% | 11 qtrs — |
| 2 | BVF INC/IL | 5.23M +— (+0.0%) | 5.23M -4.3M (-45.1%) | 4.03% -0.003 pp | 0.18% -0.210 pp | USD2.03 -50.7% | 11 qtrs — |
| 3 | BAKER BROS. ADVISORS LP | 2.78M +— (+0.0%) | 2.78M -2.3M (-45.1%) | 2.14% -0.002 pp | 0.02% -0.020 pp | USD5.80 -82.8% | 18 qtrs — |
| 4 | VANGUARD GROUP INC | 2.48M +157.8K (+6.8%) | 2.48M -1.7M (-41.3%) | 1.91% +0.120 pp | 0.00% +0.000 pp | USD3.54 -71.8% | 18 qtrs — |
| 5 | BLACKROCK, INC. | 1.85M -534.1K (-22.4%) | 1.85M -2.5M (-57.4%) | 1.42% -0.413 pp | 0.00% +0.000 pp | USD4.85 -79.4% | 6 qtrs — |
| 6 | ABRDN PLC | 1.79M +430.4K (+31.8%) | 1.79M -680.5K (-27.6%) | 1.38% +0.331 pp | 0.00% -0.001 pp | USD2.77 -63.9% | 9 qtrs — |
| 7 | DEER MANAGEMENT CO. LLC | 1.25M +— (+0.0%) | 1.25M -1.0M (-45.1%) | 0.96% -0.001 pp | 0.12% -0.082 pp | USD4.50 -77.8% | 17 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1.14M +311.2K (+37.5%) | 1.14M -369.4K (-24.5%) | 0.88% +0.239 pp | 0.00% 0.000 pp | USD1.37 -27.0% | 13 qtrs — |
| 9 | TWO SIGMA INVESTMENTS, LP | 651.2K +231.8K (+55.3%) | 651.2K -112.1K (-14.7%) | 0.50% +0.178 pp | 0.00% 0.000 pp | USD1.31 -23.7% | 8 qtrs — |
| 10 | DC FUNDS, LP | 630.0K +— (+0.0%) | 630.0K -516.6K (-45.1%) | 0.49% 0.000 pp | 43.36% +6.495 pp | USD8.34 -88.0% | 18 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 562.2K -5.5K (-1.0%) | 562.4K -471.2K (-45.6%) | 0.43% -0.005 pp | 0.00% +0.000 pp | USD4.78 -79.1% | 18 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 403.6K -62.5K (-13.4%) | 403.6K -444.7K (-52.4%) | 0.31% -0.048 pp | 0.00% 0.000 pp | USD1.42 -29.6% | 9 qtrs — |
| 13 | JANE STREET GROUP, LLC | 388.3K +307.0K (+377.5%) | 388.3K +240.3K (+162.4%) | 0.30% +0.236 pp | 0.00% +0.000 pp | USD1.09 -8.3% | 3 qtrs — |
| 14 | TWO SIGMA ADVISERS, LP | 353.9K +65.1K (+22.5%) | 353.9K -171.7K (-32.7%) | 0.27% +0.050 pp | 0.00% 0.000 pp | USD1.44 -30.6% | 4 qtrs — |
| 15 | MARSHALL WACE, LLP | 339.2K +292.6K (+627.5%) | 339.2K +254.4K (+299.7%) | 0.26% +0.225 pp | 0.00% +0.000 pp | USD1.06 -5.7% | 9 qtrs — |
| 16 | GSA CAPITAL PARTNERS LLP | 226.2K +226.2K (+100.0%) | 226.0K +226.0K (+100.0%) | 0.17% +0.174 pp | 0.02% +0.020 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 225.8K -621.7K (-73.4%) | 225.8K -1.3M (-85.4%) | 0.17% -0.479 pp | 0.00% 0.000 pp | USD2.33 -57.1% | 18 qtrs — |
| 18 | XTX TOPCO LTD | 219.0K +201.4K (+1,142.5%) | 219.0K +186.9K (+582.7%) | 0.17% +0.155 pp | 0.01% +0.004 pp | USD1.07 -6.5% | 2 qtrs — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 216.1K +136.4K (+171.0%) | 216.1K +71.0K (+48.9%) | 0.17% +0.105 pp | 0.00% +0.000 pp | USD1.32 -24.2% | 10 qtrs — |
| 20 | STATE STREET CORP | 207.3K +10.0K (+5.1%) | 207.3K -151.8K (-42.3%) | 0.16% +0.008 pp | 0.00% +0.000 pp | USD5.38 -81.4% | 18 qtrs — |
| 21 | JACOBS LEVY EQUITY MANAGEMENT, INC | 188.2K +188.2K (+100.0%) | 188.2K +188.2K (+100.0%) | 0.14% +0.145 pp | 0.00% +0.001 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 22 | CITADEL ADVISORS LLC | 162.9K -227.9K (-58.3%) | 162.9K -548.3K (-77.1%) | 0.13% -0.176 pp | 0.00% 0.000 pp | USD1.83 -45.4% | 8 qtrs — |
| 23 | BROWN BROTHERS HARRIMAN & CO | 143.1K +— (+0.0%) | 143.1K -117.3K (-45.1%) | 0.11% 0.000 pp | 0.00% -0.001 pp | USD5.48 -81.8% | 7 qtrs — |
| 24 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 115.4K -25.0K (-17.8%) | 115.4K -140.1K (-54.8%) | 0.09% -0.019 pp | 0.00% -0.003 pp | USD2.54 -60.6% | 17 qtrs — |
| 25 | NORTHERN TRUST CORP | 98.2K -350.0 (-0.4%) | 98.2K -81.2K (-45.3%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD4.44 -77.5% | 13 qtrs — |
| 26 | LETKO, BROSSEAU & ASSOCIATES INC | 95.9K +— (+0.0%) | 95.9K -78.6K (-45.1%) | 0.07% 0.000 pp | 0.00% -0.001 pp | USD1.92 -47.9% | 10 qtrs — |
| 27 | NEWEDGE WEALTH, LLC | 91.5K +— (+0.0%) | 91.5K -12.3K (-11.9%) | 0.07% 0.000 pp | 0.00% -0.001 pp | USD1.55 -35.5% | 13 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 86.9K -44.1K (-33.7%) | 86.9K -151.5K (-63.5%) | 0.07% -0.034 pp | 0.00% +0.000 pp | USD2.99 -66.6% | 9 qtrs — |
| 29 | DIMENSIONAL FUND ADVISORS LP | 74.5K -12.8K (-14.7%) | 74.5K -84.2K (-53.0%) | 0.06% -0.010 pp | 0.00% +0.000 pp | USD4.01 -75.1% | 7 qtrs — |
| 30 | STIFEL FINANCIAL CORP | 72.4K -25.0K (-25.7%) | 72.4K -104.9K (-59.2%) | 0.06% -0.019 pp | 0.00% 0.000 pp | USD2.65 -62.3% | 11 qtrs — |
| 31 | D. E. SHAW & CO., INC. | 69.4K +69.4K (+100.0%) | 69.4K +69.4K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 32 | UBS GROUP AG | 55.2K +44.1K (+398.5%) | 55.2K +35.0K (+173.9%) | 0.04% +0.034 pp | 0.00% +0.000 pp | USD1.19 -16.0% | 18 qtrs — |
| 33 | TANG CAPITAL MANAGEMENT LLC | 46.1K -553.9K (-92.3%) | 46.1K -1.0M (-95.8%) | 0.04% -0.427 pp | 0.00% -0.040 pp | USD1.71 -41.5% | 5 qtrs — |
| 34 | BANK OF AMERICA CORP /DE/ | 38.7K -184.3K (-82.6%) | 38.7K -367.2K (-90.5%) | 0.03% -0.142 pp | 0.00% +0.000 pp | USD3.54 -71.8% | 13 qtrs — |
| 35 | DC INVESTMENTS MANAGEMENT, LLC | 35.6K +— (+0.0%) | 35.6K -29.2K (-45.1%) | 0.03% +0.000 pp | 0.02% -0.011 pp | USD8.34 -88.0% | 18 qtrs — |
| 36 | JPMORGAN CHASE & CO | 33.3K -204.4K (-86.0%) | 33.3K -399.4K (-92.3%) | 0.03% -0.158 pp | 0.00% +0.000 pp | USD2.10 -52.4% | 9 qtrs — |
| 37 | ACADIAN ASSET MANAGEMENT LLC | 29.5K +29.5K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 26.4K -3.5K (-11.8%) | 26.4K -28.0K (-51.5%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD2.79 -64.2% | 5 qtrs — |
| 39 | HRT FINANCIAL LP | 26.6K +26.6K (+100.0%) | 26.0K +26.0K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 3 qtrs — |
| 40 | PANAGORA ASSET MANAGEMENT INC | 25.3K +25.3K (+100.0%) | 25.3K +25.3K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 41 | HSBC HOLDINGS PLC | 24.6K +— (+0.0%) | 24.8K -19.0K (-43.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.38 -27.5% | 4 qtrs — |
| 42 | PRUDENTIAL FINANCIAL INC | 24.4K +12.9K (+112.2%) | 24.4K +3.5K (+16.6%) | 0.02% +0.010 pp | 0.00% +0.000 pp | USD1.39 -28.1% | 5 qtrs — |
| 43 | BARCLAYS PLC | 23.2K -34.9K (-60.1%) | 23.2K -266.0K (-92.0%) | 0.02% -0.027 pp | 0.00% 0.000 pp | USD2.94 -66.0% | 7 qtrs — |
| 44 | LPL FINANCIAL LLC | 22.5K +1.0K (+4.7%) | 22.5K -16.6K (-42.5%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD1.78 -43.8% | 2 qtrs — |
| 45 | NEUBERGER BERMAN GROUP LLC | 18.4K +— (+0.0%) | 18.4K -15.1K (-45.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.45 -31.0% | 3 qtrs — |
| 46 | R SQUARED LTD | 16.0K -2.8K (-14.8%) | 16.0K -18.2K (-53.2%) | 0.01% -0.002 pp | 0.01% -0.007 pp | USD1.60 -37.5% | 3 qtrs — |
| 47 | TWO SIGMA SECURITIES, LLC | 15.9K +15.9K (+100.0%) | 15.9K +15.9K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.002 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 48 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 14.7K -6.3K (-30.1%) | 14.7K -23.5K (-61.6%) | 0.01% -0.005 pp | 0.00% 0.000 pp | USD1.47 -32.0% | 3 qtrs — |
| 49 | POINT72 ASSET MANAGEMENT, L.P. | 14.5K +14.5K (+100.0%) | 14.5K +14.5K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 50 | ADVISOR GROUP HOLDINGS, INC. | 12.2K +— (+0.0%) | 12.2K -9.6K (-44.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD5.16 -80.6% | 7 qtrs — |
| 51 | MIZUHO SECURITIES USA LLC | 10.0K +10.0K (+100.0%) | 10.1K +10.1K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 52 | ARIES WEALTH MANAGEMENT | 10.0K +— (+0.0%) | 10.0K -8.2K (-45.1%) | 0.01% +0.000 pp | 0.00% -0.002 pp | USD2.56 -60.9% | 10 qtrs — |
| 53 | WALDRON PRIVATE WEALTH LLC | 10.0K +— (+0.0%) | 10.0K -8.2K (-45.1%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD2.10 -52.4% | 12 qtrs — |
| 54 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.8K -4.3K (-39.1%) | 6.8K -13.5K (-66.6%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD3.40 -70.6% | 9 qtrs — |
| 55 | FEDERATED HERMES, INC. | 5.0K +2.8K (+128.7%) | 5.0K +1.0K (+25.7%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.17 -14.5% | 4 qtrs — |
| 56 | FMR LLC | 500.00 -9.5K (-95.0%) | 500.00 -17.7K (-97.3%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD1.53 -34.6% | 6 qtrs — |
| 57 | SBI SECURITIES CO., LTD. | 392.00 +180.0 (+84.9%) | 392.00 +6.0 (+1.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.46 -31.5% | 5 qtrs — |
| 58 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 200.00 +— (+0.0%) | 200.00 -164.0 (-45.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.82 -45.1% | 2 qtrs — |
| 59 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8.00 +8.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +0.0% | 1 qtrs NEW |
| 60 | CITIGROUP INC | — -1.1K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 61 | MARINER, LLC | — -16.0K (-100.0%) | — -29.2K (-100.0%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 62 | MILITIA CAPITAL PARTNERS, LP | — -102.1K (-100.0%) | — -185.8K (-100.0%) | 0.00% -0.079 pp | 0.00% -0.086 pp | USD— | 3 qtrs SOLD |
| 63 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -2.0K (-100.0%) | — -3.7K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 64 | NISA INVESTMENT ADVISORS, LLC | — -593.0 (-100.0%) | — -1.1K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 65 | CATALYST FUNDS MANAGEMENT PTY LTD | — -30.8K (-100.0%) | — -56.0K (-100.0%) | 0.00% -0.024 pp | 0.00% -0.009 pp | USD— | 3 qtrs SOLD |
| 66 | PROPEL BIO MANAGEMENT, LLC | — -1.9M (-100.0%) | — -3.5M (-100.0%) | 0.00% -1.490 pp | 0.00% -3.521 pp | USD— | 9 qtrs SOLD |
| 67 | QUADRATURE CAPITAL LTD | — -56.7K (-100.0%) | — -103.4K (-100.0%) | 0.00% -0.044 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 68 | QUBE RESEARCH & TECHNOLOGIES LTD | — -27.7K (-100.0%) | — -50.4K (-100.0%) | 0.00% -0.021 pp | 0.00% 0.000 pp | USD— | 10 qtrs SOLD |
| 69 | RIALTO WEALTH MANAGEMENT, LLC | — -381.0 (-100.0%) | — -694.0 (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 70 | ROYAL BANK OF CANADA | — -806.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 71 | SIMPLIFY ASSET MANAGEMENT INC. | — -905.0K (-100.0%) | — -1.6M (-100.0%) | 0.00% -0.698 pp | 0.00% -0.030 pp | USD— | 12 qtrs SOLD |
| 72 | GF FUND MANAGEMENT CO. LTD. | — -1.0K (-100.0%) | — -1.9K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 73 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -9.2K (-100.0%) | — -16.7K (-100.0%) | 0.00% -0.007 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 74 | TRUE WEALTH DESIGN, LLC | — -9.0 (-100.0%) | — -17.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 75 | ALPHABET INC. | — -1.1M (-100.0%) | — -2.0M (-100.0%) | 0.00% -0.830 pp | 0.00% -0.081 pp | USD— | 18 qtrs SOLD |
| 76 | ALGERT GLOBAL LLC | — -28.0K (-100.0%) | — -51.0K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.001 pp | USD— | 3 qtrs SOLD |
| 77 | EVERSOURCE WEALTH ADVISORS, LLC | — -65.0 (-100.0%) | — -118.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 78 | VIRTU FINANCIAL LLC | — -60.5K (-100.0%) | — -110.0K (-100.0%) | 0.00% -0.047 pp | 0.00% -0.006 pp | USD— | 4 qtrs SOLD |
| 79 | VOLEON CAPITAL MANAGEMENT LP | — -47.9K (-100.0%) | — -87.1K (-100.0%) | 0.00% -0.037 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 182.6K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 607.6K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.4K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 9.4K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 696.49 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.61M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.5K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.9K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 776.68 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 85.60 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
2.39M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,385,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-20 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 1.12 | 392.0K | 350,000 | D | ↗ |
| 2026-01-20 | MacBeath Gavin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,165,000 | 1.12 | 1.30M | 1,165,000 | D | ↗ |
| 2026-01-20 | Louis Chrystal | Officer | A-Award | A | Stock Option (Right to Buy) | 420,000 | 1.12 | 470.4K | 420,000 | D | ↗ |
| 2026-01-20 | Dworak Leiden | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.12 | 112.0K | 100,000 | D | ↗ |
| 2026-01-20 | Amello Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 1.12 | 392.0K | 350,000 | D | ↗ |
| 2025-12-23 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 6,232 | 0.90 | 5.6K | 8,019,148 | I | ↗ |
| 2025-12-22 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 75,500 | 0.90 | 68.0K | 8,012,916 | I | ↗ |
| 2025-12-19 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 80,069 | 0.90 | 72.0K | 7,937,416 | I | ↗ |
| 2025-08-14 | Dworak Leiden | Officer | — | — | Stock Option (Right to Buy) | 46,875 | 6.00 | 281.3K | 0 | D | ↗ |
| 2025-06-30 | Woods Keith | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 1.45 | 97.2K | 67,000 | D | ↗ |
| 2025-06-30 | Nicholson Garry A | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 1.45 | 97.2K | 67,000 | D | ↗ |
| 2025-06-30 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 1.45 | 97.2K | 67,000 | D | ↗ |
| 2025-06-30 | Gruia Gabriela | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 1.45 | 97.2K | 67,000 | D | ↗ |
| 2025-06-30 | Dorton Katina | Director | A-Award | A | Stock Option (Right to Buy) | 67,000 | 1.45 | 97.2K | 67,000 | D | ↗ |
| 2025-06-30 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 67,000 | 1.45 | 97.2K | 67,000 | I | ↗ |
| 2025-05-20 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 1,200,000 | 1.20 | 1.44M | 7,946,141 | I | ↗ |
| 2025-05-19 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 1,388,794 | 1.20 | 1.67M | 6,746,141 | I | ↗ |
| 2025-01-03 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 3.07 | 766.3K | 250,000 | D | ↗ |
| 2025-01-03 | MacBeath Gavin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 800,000 | 3.07 | 2.45M | 800,000 | D | ↗ |
| 2025-01-03 | Louis Chrystal | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 3.07 | 1.23M | 400,000 | D | ↗ |
| 2025-01-03 | Amello Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 3.07 | 827.6K | 270,000 | D | ↗ |
| 2024-12-26 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Pre-funded Warrant (right to buy) | 7,500,000 | 0.00 | 750.00 | 7,500,000 | I | ↗ |
| 2024-12-13 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 2.90 | 290.1K | 5,357,347 | I | ↗ |
| 2024-12-12 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 31,800 | 3.01 | 95.6K | 5,257,347 | I | ↗ |
| 2024-11-15 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share | 947 | 4.34 | 4.1K | 5,225,547 | I | ↗ |
| 2024-09-23 | Klencke Barbara | Director | P-Purchase | A | Voting Common Stock | 5,000 | 5.29 | 26.5K | 45,000 | D | ↗ |
| 2024-08-26 | Klencke Barbara | Director | P-Purchase | A | Voting Common Stock | 5,000 | 5.53 | 27.7K | 40,000 | — | ↗ |
| 2024-08-23 | ZDRAVESKI ZORAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 3.27 | 81.8K | 25,000 | — | ↗ |
| 2024-08-23 | Klencke Barbara | Director | P-Purchase | A | Voting Common Stock | 5,000 | 5.69 | 28.5K | 35,000 | — | ↗ |
| 2024-06-12 | Woods Keith | Director | A-Award | A | Stock Option (Right to Buy) | 47,500 | 8.88 | 421.8K | 47,500 | — | ↗ |
| 2024-06-12 | Nicholson Garry A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 47,500 | 8.88 | 421.8K | 47,500 | — | ↗ |
| 2024-06-12 | Gruia Gabriela | Director | A-Award | A | Stock Option (Right to Buy) | 47,500 | 8.88 | 421.8K | 47,500 | — | ↗ |
| 2024-06-12 | Dorton Katina | Director | A-Award | A | Stock Option (Right to Buy) | 47,500 | 8.88 | 421.8K | 47,500 | — | ↗ |
| 2024-06-12 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 47,500 | 8.88 | 421.8K | 47,500 | — | ↗ |
| 2024-05-01 | Louis Chrystal | Officer | A-Award | A | Stock Option (Right to Buy) | 380,000 | 8.62 | 3.28M | 380,000 | — | ↗ |
| 2024-04-22 | Louis Chrystal | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-19 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Pre-funded Warrant (right to buy) | 5,000,000 | 0.00 | 500.00 | 5,000,000 | — | ↗ |
| 2024-04-19 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Warrants to purchase Common Stock | 8,851,451 | 0.00 | 885.15 | 43,158,741 | — | ↗ |
| 2024-02-01 | Amello Jason | Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 5.15 | 3.86M | 750,000 | — | ↗ |
| 2024-01-29 | Amello Jason | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-12 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 6.00 | 315.0K | 52,500 | D | ↗ |
| 2024-01-12 | MacBeath Gavin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 6.00 | 960.0K | 160,000 | D | ↗ |
| 2024-01-12 | Dworak Leiden | Other | A-Award | A | Stock Option (Right to Buy) | 46,875 | 6.00 | 281.3K | 46,875 | D | ↗ |
| 2023-12-19 | BARBERICH TIMOTHY J | Director | P-Purchase | A | Voting Common Stock | 317 | 4.97 | 1.6K | 67,027 | — | ↗ |
| 2023-12-18 | BARBERICH TIMOTHY J | Director | P-Purchase | A | Voting Common Stock | 28,830 | 4.89 | 140.9K | 66,710 | — | ↗ |
| 2023-12-14 | Klencke Barbara | Director | P-Purchase | A | Voting Common Stock | 5,000 | 5.08 | 25.4K | 30,000 | — | ↗ |
| 2023-12-06 | Woods Keith | Director | A-Award | A | Stock Option (Right to Buy) | 17,500 | 6.74 | 118.0K | 17,500 | — | ↗ |
| 2023-07-21 | Dworak Leiden | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.23 | 55.8K | 25,000 | — | ↗ |
| 2023-06-13 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 430,000 | 2.49 | 1.07M | 430,000 | — | ↗ |
| 2023-06-13 | Silver Brian M. | Officer | A-Award | A | Stock Option (Right to Buy) | 632,500 | 2.49 | 1.57M | 632,500 | — | ↗ |
| 2023-06-13 | MacBeath Gavin | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,121,300 | 2.49 | 2.79M | 1,121,300 | — | ↗ |
| 2023-06-13 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 36,524 | 2.66 | 97.2K | 36,524 | — | ↗ |
| 2023-06-13 | Gruia Gabriela | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.66 | 93.1K | 35,000 | — | ↗ |
| 2023-06-13 | Dorton Katina | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.66 | 93.1K | 35,000 | — | ↗ |
| 2023-06-13 | Barton Debora | Officer | A-Award | A | Stock Option (Right to Buy) | 430,000 | 2.49 | 1.07M | 430,000 | — | ↗ |
| 2023-06-13 | BARBERICH TIMOTHY J | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 2.66 | 93.1K | 35,000 | — | ↗ |
| 2023-06-13 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 35,000 | 2.66 | 93.1K | 35,000 | — | ↗ |
| 2023-06-02 | BARBERICH TIMOTHY J | Director | P-Purchase | A | Voting Common Stock | 37,880 | 2.63 | 99.6K | 37,880 | — | ↗ |
| 2023-06-01 | BAKER BROS. ADVISORS LP | Director | A-Award | A | Warrants to purchase Common Stock | 34,307,290 | 0.00 | 3.4K | 34,307,290 | — | ↗ |
| 2023-05-31 | Lynx1 Capital Management LP | 10% Owner | S-Sale | D | Common stock, $0.0001 par value per share Common Stock | 10,000 | 2.51 | 25.1K | 5,240,000 | — | ↗ |
| 2023-05-26 | EcoR1 Capital, LLC | 10% Owner | — | I | Voting Common Stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2023-04-06 | Klencke Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 9,146 | 2.20 | 20.1K | 9,146 | — | ↗ |
| 2023-02-02 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.81 | 63.4K | 35,000 | — | ↗ |
| 2023-02-02 | SOUTHWELL DAVID P | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.81 | 181.0K | 100,000 | — | ↗ |
| 2023-02-02 | MacBeath Gavin | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.81 | 72.4K | 40,000 | — | ↗ |
| 2023-02-02 | Barton Debora | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.81 | 90.5K | 50,000 | — | ↗ |
| 2022-12-28 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 3,158 | 1.56 | 4.9K | 32,885 | — | ↗ |
| 2022-12-27 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 2,842 | 1.50 | 4.3K | 29,727 | — | ↗ |
| 2022-07-25 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-07-25 | Silver Brian M. | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2022-07-25 | SOUTHWELL DAVID P | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-07-25 | MacBeath Gavin | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-07-25 | Desmarais William | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-07-05 | Barton Debora | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-06-01 | Harel Ittai | Director | A-Award | A | Stock Option (Right to Buy) | 9,146 | 0.00 | — | 9,146 | — | ↗ |
| 2022-06-01 | Gruia Gabriela | Director | A-Award | A | Stock Option (Right to Buy) | 9,146 | 0.00 | — | 9,146 | — | ↗ |
| 2022-06-01 | Dorton Katina | Director | A-Award | A | Stock Option (Right to Buy) | 9,146 | 0.00 | — | 9,146 | — | ↗ |
| 2022-06-01 | Baker Brothers Life Sciences LP | Director | A-Award | A | Non- Qualified Stock Option (right to buy) | 9,146 | 0.00 | — | 9,146 | — | ↗ |
| 2022-06-01 | BARBERICH TIMOTHY J | Director | A-Award | A | Stock Option (Right to Buy) | 9,146 | 0.00 | — | 9,146 | — | ↗ |
| 2022-06-01 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Option (right to buy) | 9,146 | 3.17 | 29.0K | 9,146 | — | ↗ |
| 2022-05-18 | SOUTHWELL DAVID P | Director / Officer | P-Purchase | A | Voting Common Stock | 10,000 | 3.55 | 35.5K | 171,569 | — | ↗ |
| 2022-05-11 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 22,983 | 1.99 | 45.6K | 2,528,583 | — | ↗ |
| 2022-05-10 | Baker Brothers Life Sciences LP | Director | P-Purchase | A | Common Stock | 22,983 | 1.99 | 45.6K | 2,528,583 | — | ↗ |
| 2022-05-10 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Common Stock | 758,094 | 1.95 | 1.48M | 2,505,600 | — | ↗ |
| 2022-03-24 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 15,000 | 3.40 | 51.0K | 26,885 | — | ↗ |
| 2022-01-18 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 4.85 | 412.3K | 85,000 | — | ↗ |
| 2022-01-18 | Silver Brian M. | Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 4.85 | 557.8K | 115,000 | — | ↗ |
| 2022-01-18 | SOUTHWELL DAVID P | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 4.85 | 1.33M | 275,000 | — | ↗ |
| 2022-01-18 | MacBeath Gavin | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 4.85 | 679.0K | 140,000 | — | ↗ |
| 2022-01-18 | Desmarais William | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.85 | 242.5K | 50,000 | — | ↗ |
| 2021-12-23 | SOUTHWELL DAVID P | Director / Officer | M-Exempt | A | Voting Common Stock | 48,670 | 1.97 | 95.9K | 146,569 | — | ↗ |
| 2021-09-23 | ZDRAVESKI ZORAN | Officer | P-Purchase | A | Voting Common Stock | 4,716 | 7.48 | 35.3K | 4,716 | — | ↗ |
| 2021-09-21 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 5,000 | 6.32 | 31.6K | 11,885 | — | ↗ |
| 2021-09-21 | MacBeath Gavin | Officer | P-Purchase | A | Voting Common Stock | 57 | 6.19 | 352.72 | 49,767 | — | ↗ |
| 2021-09-20 | MacBeath Gavin | Officer | P-Purchase | A | Voting Common Stock | 4,943 | 6.22 | 30.7K | 49,710 | — | ↗ |
| 2021-09-09 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 5,885 | 8.48 | 49.9K | 6,885 | — | ↗ |
| 2021-09-08 | SOUTHWELL DAVID P | Director / Officer | P-Purchase | A | Voting Common Stock | 11,000 | 8.73 | 96.1K | 97,899 | — | ↗ |
| 2021-09-07 | ZDRAVESKI ZORAN | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 8.99 | 1.35M | 150,000 | — | ↗ |
| 2021-08-27 | Desmarais William | Officer | P-Purchase | A | Voting Common Stock | 2,500 | 9.08 | 22.7K | 2,500 | — | ↗ |
| 2021-07-20 | Westphal Christoph H | 10% Owner | C-Conversion | D | Series C Preferred Stock | 171,063 | 0.00 | — | 0 | — | ↗ |
| 2021-07-20 | Silver Brian M. | Officer | P-Purchase | A | Voting Common Stock | 1,000 | 15.00 | 15.0K | 1,000 | — | ↗ |
| 2021-07-20 | BARBERICH TIMOTHY J | Director | C-Conversion | D | Series B Preferred Stock | 33,259 | 0.00 | — | 0 | — | ↗ |
| 2021-07-20 | BAKER BROS. ADVISORS LP | Director | P-Purchase | A | Common Stock | 104,698 | 15.00 | 1.57M | 104,698 | — | ↗ |
| 2021-07-15 | Westphal Christoph H | Director / 10% Owner | — | I | Series C Preferred Stock | 171,063 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Silver Brian M. | Officer | — | D | Stock Option (right to buy) | 48,780 | 5.82 | 283.9K | 0 | — | ↗ |
| 2021-07-15 | SOUTHWELL DAVID P | Director / Officer | — | D | Employee Stock Option (right to buy) | 200,822 | 2.46 | 494.0K | 0 | — | ↗ |
| 2021-07-15 | MacBeath Gavin | Officer | — | D | Voting Common Stock | 0 | 0.00 | — | 44,767 | — | ↗ |
| 2021-07-15 | Harel Ittai | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Gruia Gabriela | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Dorton Katina | Director | — | D | Stock Option (right to buy) | 48,780 | 11.56 | 563.9K | 0 | — | ↗ |
| 2021-07-15 | Desmarais William | Officer | — | D | Employee Stock Option (right to buy) | 119,688 | 13.94 | 1.67M | 0 | — | ↗ |
| 2021-07-15 | Biggar Stephen R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | BARBERICH TIMOTHY J | Director | — | D | Series B Preferred Stock | 33,259 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | BAKER BROS. ADVISORS LP | Director / 10% Owner | — | I | Series C Convertible Preferred Stock | 3,960,811 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.5K
Shares Outstanding
55.82M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gavin MacBeath, Ph.D. Chief Executive Officer and Director | 665.0K | — | — | 1.98M | 139.7K | 14.0K | 2.80M | 70.78% | ↗ |
| 2 | 2025 | Chrystal Louis, M.D., M.P.H. Chief Medical Officer | 530.0K | — | — | 991.4K | 74.2K | 14.0K | 1.61M | 61.59% | ↗ |
| 3 | 2025 | Jason A. Amello Chief Financial Officer and Treasurer | 520.0K | — | — | 669.2K | 72.8K | 14.0K | 1.28M | 52.44% | ↗ |
| 4 | 2024 | Jason A. Amello Chief Financial Officer and Treasurer | 463.5K | 60.0K | — | 2.97M | 230.0K | 13.8K | 3.73M | 79.45% | ↗ |
| 5 | 2024 | Chrystal Louis, M.D., M.P.H. Chief Medical Officer | 343.1K | 45.0K | — | 2.48M | 162.0K | — | 3.03M | 81.85% | ↗ |
| 6 | 2024 | Gavin MacBeath, Ph.D. Chief Executive Officer and Director | 620.0K | — | — | 734.9K | 392.0K | 13.7K | 1.76M | 41.74% | ↗ |
| 7 | 2023 | Gavin MacBeath, Ph.D. Chief Executive Officer and Director | 545.1K | — | — | 2.34M | 296.0K | 12.4K | 3.20M | 73.29% | ↗ |
| 8 | 2023 | Debora Barton, M.D. Former Chief Medical Officer | 472.5K | — | — | 944.9K | 217.0K | 75.6K | 1.71M | 55.25% | ↗ |
| 9 | 2023 | Brian Silver, J.D. Former Chief Financial Officer and Treasurer | 283.1K | — | — | 1.29M | — | 10.2K | 1.58M | 81.48% | ↗ |
| 10 | 2023 | Zoran Zdraveski, J.D., Ph.D. Chief Legal and Strategy Officer and Secretary | 441.0K | — | — | 924.6K | 203.0K | 13.2K | 1.58M | 58.45% | ↗ |
| 11 | 2023 | David Southwell Former President, Chief Executive Officer and Director | 153.5K | — | — | 135.3K | — | 1.00M | 1.29M | 10.46% | ↗ |
| 12 | 2022 | David Southwell Former President, Chief Executive Officer and Director | 622.2K | — | — | 1.17M | 342.2K | 8.9K | 2.14M | 54.57% | ↗ |
| 13 | 2022 | Brian Silver, J.D. Former Chief Financial Officer and Treasurer | 480.0K | — | — | 910.9K | 192.0K | 18.2K | 1.60M | 56.89% | ↗ |
| 14 | 2022 | Brian Silver, J.D. Chief Financial Officer and Treasurer | 480.0K | — | — | 910.9K | 192.0K | 18.2K | 1.60M | 56.89% | ↗ |
| 15 | 2022 | Gavin MacBeath, Ph.D. Chief Executive Officer and Director | 450.0K | — | — | 711.6K | 188.0K | 12.2K | 1.36M | 52.25% | ↗ |
| 16 | 2022 | Gavin MacBeath, Ph.D. Acting Chief Executive Officer, Chief Scientific and Operating Officer | 450.0K | — | — | 711.6K | 188.0K | 12.2K | 1.36M | 52.25% | ↗ |
| 17 | 2021 | Brian Silver, J.D. Chief Financial Officer and Treasurer | 305.0K | — | — | 2.74M | 122.0K | 17.0K | 3.18M | 86.05% | ↗ |
| 18 | 2021 | David Southwell Former President, Chief Executive Officer and Director | 564.5K | — | — | 1.92M | 310.4K | 8.9K | 2.81M | 68.52% | ↗ |
| 19 | 2021 | David Southwell President, Chief Executive Officer and Director | 550.0K | — | — | 1.92M | 302.5K | 8.9K | 2.79M | 69.07% | ↗ |
| 20 | 2021 | Gavin MacBeath, Ph.D. Chief Scientific Officer | 400.0K | — | — | 618.0K | 160.0K | 11.8K | 1.19M | 51.94% | ↗ |
| 21 | 2021 | Gavin MacBeath, Ph.D. Acting Chief Executive Officer, Chief Scientific and Operating Officer | 400.0K | — | — | 618.0K | 160.0K | 11.8K | 1.19M | 51.94% | ↗ |
| 22 | 2020 | David Southwell President, Chief Executive Officer and Director | 466.7K | — | — | — | 275.4K | 8.2K | 750.2K | 0.00% | ↗ |
| 23 | 2020 | Gavin MacBeath, Ph.D. Chief Scientific Officer | 350.2K | — | — | — | 171.6K | 11.2K | 533.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gavin MacBeath | Chief Executive Officer & Director | 818.7K | — |
| Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary | 657.2K | — |
| Chrystal U. Louis | Chief Medical Officer | 618.2K | — |
| Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer | 606.8K | male |
| Ray Lockard | Chief Manufacturing & Quality Officer | — | male |
| Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine | — | — |
| Stephen Camiolo | Senior Vice President of Market Access | — | male |
| Stephen J. Elledge | Co-Founder & Chairman of Scientific Advisory Board | — | — |
| Tomasz Kula | Co-Founder & Member of Advisory Board | — | male |
| Leiden Dworak | VP of Finance & Principal Accounting Officer | — | male |
| Cagan Gurer | Senior Vice President of Discovery | — | male |
| Jim Murray | Chief Development Operations Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TCRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
